Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHX9 | Q08211 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 14/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25369081 | 1.00 | DHX9 (0.48) | DHX9ACKR3METJAK2JAK3 | |
| SCHEMBL30543950 | 0.86 | DHX9 (0.47) | DHX9MET | |
| SCHEMBL25368505 | 0.86 | DHX9 (0.47) | DHX9MET | |
| SCHEMBL30543936 | 0.85 | NPC1 (0.56) | RAB9A | |
| SCHEMBL25370105 | 0.85 | NPC1 (0.56) | RAB9A | |
| SCHEMBL25369232 | 0.82 | KDM1A (0.46) | DHX9GAA | |
| SCHEMBL30543959 | 0.82 | KDM1A (0.46) | DHX9GAA | |
| SCHEMBL25370300 | 0.82 | ALDH1A1 (0.51) | RAB9A | |
| SCHEMBL30543961 | 0.82 | ALDH1A1 (0.51) | RAB9A | |
| SCHEMBL25368280 | 0.81 | DHX9 (0.53) | DHX9GAAHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | DHX9 1/4885ACKR3 3952/4885MET 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.